PITTSBURGH, Aug. 27 (HSMN NewsFeed) — Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has begun to market 1% Clindamycin and 5% Benzoyl Peroxide Gel based on an agreement with licensing partner Dow Lab…
Biopharmaceuticals, Generics, Dermatology
Mylan, Clindamycin, Benzoyl Peroxide, BenzaClin, sanofi-aventis, acne

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment”
Leave a Comment